DCPH Deciphera Pharmaceuticals
- 14.670
- +0.090+0.62%
Deciphera Pharmaceuticals News
Piper Sandler Sticks to Their Buy Rating for Deciphera Pharmaceuticals (DCPH)
Analysts Have Conflicting Sentiments on These Healthcare Companies: Deciphera Pharmaceuticals (DCPH) and Shockwave Medical (SWAV)
Barclays Keeps Their Sell Rating on Deciphera Pharmaceuticals (DCPH)
Buy Rating Reaffirmed for Deciphera Pharmaceuticals on Strong Q4 Performance and Promising Drug Prospects
Deciphera Pharmaceuticals (DCPH) Gets a Sell From Barclays
Analysts Are Bullish on Top Healthcare Stocks: Deciphera Pharmaceuticals (DCPH), ACADIA Pharmaceuticals (ACAD)
Deciphera Pharmaceuticals: Strong Buy Rating on Robust Financials and Promising Pipeline
Deciphera Pharmaceuticals: Sustained Growth and Market Expansion Drive Buy Rating
Piper Sandler Remains a Buy on Deciphera Pharmaceuticals (DCPH)
Stifel Nicolaus Sticks to Their Buy Rating for Deciphera Pharmaceuticals (DCPH)
JP Morgan Reinstates Neutral on Deciphera Pharmaceuticals, Announces $14 Price Target
Deciphera Pharmaceuticals Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Deciphera Pharmaceuticals (DCPH) and Ocular Therapeutix (OCUL)
Promising Clinical Trial Results and Financial Performance Lead to Deciphera Pharmaceuticals' Buy Rating Upgrade
Stifel Maintains Buy on Deciphera Pharmaceuticals, Raises Price Target to $22
Deciphera Pharmaceuticals Analyst Ratings
Jones Research Upgrades Deciphera to Buy From Hold
HC Wainwright & Co. Maintains Buy on Deciphera Pharmaceuticals, Raises Price Target to $30
Deciphera Pharmaceuticals Earns Buy Rating: Superior Performance and Safety Profile of Vimseltinib Reinforces Market Potential
Piper Sandler Upgrades Deciphera Pharmaceuticals to Overweight, Raises Price Target to $23
Analysis
Price Target
No Data
